Abstract
In patients with relapsed/refractory Burkitt lymphoma (r/r BL), overall survival (OS) is poor, and effective therapies and evidence for the best therapy are lacking. The monoclonal antibody blinatumomab may represent a novel option. However, only limited data on the use of blinatumomab in r/r BL are so far available. This multi-center, retrospective case series investigated nine patients with r/r BL treated with blinatumomab. The safety of blinatumomab was assessed with respect to frequency and severity of adverse effects (AEs) infections, cytokine release syndrome (CRS) and neurotoxicity. Progression-free survival (PFS), OS and overall response rate (ORR) were analyzed to assess efficacy. No AEs > grade 2 occurred, and AEs were generally treatable and fully reversible. The best response to blinatumomab was complete remission in 3/9 patients and partial remission in 2/9, whilst 4/9 presented with progressive disease. Median PFS and OS were 2 and 6 months, respectively, ranging from 5 days to 32 months and 11 days to 32 months, respectively. Blinatumomab treatment was a successful bridging treatment to stem cell transplantation in 3/9 patients. The response to blinatumomab varied widely, and only one patient survived longer term, but activity in patients with r/r BL was evident in some patients, with its use being safe, warranting its prospective investigation.
Reference32 articles.
1. Chamuleau, M.E.D., Stenner, F., Chitu, D., Novak, U., Minnema, M., Visser, O., Stevens, W., Zenz, T., van Imhoff, G., and Wu, K.L. (2022, January 9–12). R-CODOX-M/R-IVAC Versus DA-EPOCH-R in Patients with Newly Diagnosed High-Risk Burkitt Lymphoma: First Results of a Multi-Center Randomized HOVON/SAKK Trial. Proceedings of the EHA Congress Vienna AAL, Vienna, Austria.
2. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens;Oosten;Ann. Hematol.,2018
3. The treatment of Burkitt lymphoma in adults;Crombie;Blood.,2021
4. Burkitt lymphoma in the modern era: Real-world outcomes and prognostication across 30 US cancer centers;Evens;Blood,2021
5. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens;Kelly;Clin. Lymphoma Myeloma,2009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Antineoplastics;Reactions Weekly;2023-10-14